MedTrace Logo

Effect of Nebulized Bronchodilators on Heart Rate

NCT01151579 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2015-10-23

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.

Conditions

Interventions

DRUG

Levalbuterol

inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg

DRUG

Albuterol

Nebulized albuterol 2.5mg

Sponsors & Collaborators

  • Ascension Health

    collaborator INDUSTRY

  • Fahim Khorfan, MD

    lead INDUSTRY

Principal Investigators

  • Fahim Khorfan, MD · Ascension Health

  • Kimberly R Barber, PhD · Ascension Health

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151579 on ClinicalTrials.gov